BusinessTeneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific AntibodiesBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessTeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of HematologyBy Nasdaq OMXDec 11, 2017, 1:00 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessTeneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
BusinessOncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian CancerBy Nasdaq OMXFeb 13, 2017, 1:31 PM UTC
BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
